Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

Baxter International logo
Baxter InternationalBAX
-$152M-485%
Amgen logo
AmgenAMGN
——
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's increase (decrease) in accounts receivable?
Halozyme Therapeutics (HALO) reported increase (decrease) in accounts receivable of $19.55M in Q1 2026.
How has Halozyme Therapeutics's increase (decrease) in accounts receivable changed year-over-year?
Halozyme Therapeutics's increase (decrease) in accounts receivable increased by 609.8% year-over-year, from -$3.83M to $19.55M.
What is the long-term trend for Halozyme Therapeutics's increase (decrease) in accounts receivable?
Over 4 years (2021 to 2025), Halozyme Therapeutics's increase (decrease) in accounts receivable has grown at a 108.7% compound annual growth rate (CAGR), from -$6.76M to $128.06M.